Cholecystokinin and pain: a review.
The recent discovery that cholecystokinin (CCK) is present in the nervous system has prompted studies that have nearly proven its neurotransmitter status. Pain modulation appears to be a major effect of CCK and proglumide, its antagonist. CCK's inhibitory effect and proglumide's potentiating effect on opiate analgesia may have clinical application; proglumide's inhibitory effect on opiate tolerance may help in management of chronic pain. More research is required before the CCK/opiate interaction can be exploited on a large scale to relieve pain.
McRoberts
J W
JW
D002766:Cholecystokinin / Q000032:analysis / Q000037:antagonists & inhibitors / Q000502:physiology*; D006801:Humans; D018377:Neurotransmitter Agents; D010146:Pain / Q000188:drug therapy / Q000503:physiopathology*; D010487:Periaqueductal Gray / Q000032:analysis; D011377:Proglumide / Q000494:pharmacology; D011957:Receptors, Opioid / Q000502:physiology
D018377:Neurotransmitter Agents; D011957:Receptors, Opioid; D002766:Cholecystokinin; D011377:Proglumide